Drug intelligence / Profile preview

Nycoplus Magnesium

Development stage: Unknown
Lead developer: Orifarm Group
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Nycoplus Magnesium is a mineral supplement manufactured by Orifarm Healthcare AS. It contains magnesium, an essential mineral contributing to normal energy turnover, muscle function, reduction of fatigue and exhaustion, electrolyte balance, and cell division processes. It is primarily indicated for the treatment and prevention of magnesium deficiency caused by reduced intake, reduced absorption, or increased loss.

Brand names: Nycoplus Magnesium

Beyond the preview

Go deeper on Nycoplus Magnesium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nycoplus Magnesium.

Explore the full profile